Home  »  Finance   »  Digging Up the Details on ImmunoGen, Inc. (IMGN)...

Digging Up the Details on ImmunoGen, Inc. (IMGN)

On Tuesday, shares of ImmunoGen, Inc. (NASDAQ:IMGN) marked $5.25 per share versus a previous $5.65 closing price. With having a -7.08% loss, an insight into the fundamental values of ImmunoGen, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. IMGN showed a rise of 2.84% within its YTD performance, with highs and lows between $1.95 – $7.07 during the period of 52 weeks, compared to the simple moving average of 23.61% in the period of the last 200 days.

Guggenheim equity researchers changed the status of ImmunoGen, Inc. (NASDAQ: IMGN) shares from “Neutral” to a “Buy” rating in the report published on October 2nd, 2020. Other analysts, including JP Morgan, also published their reports on IMGN shares. JP Morgan repeated the rating from the previous report, marking IMGN under “Neutral” rating, in the report published on September 29th, 2020. Additionally, IMGN shares got another “Buy” rating from H.C. Wainwright, setting a target price of $9 on the company’s shares, according to the report published in December 17th, 2019. On August 13th, 2019, H.C. Wainwright Reiterated an Buy rating and increased its price target from $4 to $5. On the other hand, Guggenheim Downgrade the “Neutral” rating for IMGN shares, as published in the report on May 15th, 2019. H.C. Wainwright seems to be going bullish on the price of IMGN shares, based on the price prediction for IMGN, indicating that the shares will jump to $7, giving the shares “Buy” rating based on their report from May 6th, 2019. Another “Outperform” rating came from Cowen.

[bold-text]ImmunoGen, Inc. (IMGN) Analysis[/bold-text]

The present dividend yield for IMGN owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -3.20%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of ImmunoGen, Inc. (IMGN) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of 147.30% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while IMGN is currently recording an average of 2.56M in volumes. The volatility of the stock on monthly basis is set at 7.44%, while the weekly volatility levels are marked at 9.63%with 4.58% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $8.11, indicating growth from the present price of $5.25, which can represent yet another valuable research and analysis points that can help you decide whether to invest in IMGN or pass.

[bold-text]What to Look for When Analyzing ImmunoGen, Inc. Shares?[/bold-text]

ImmunoGen, Inc. (IMGN) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare IMGN shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for ImmunoGen, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -0.43 is supported by the yearly EPS growth of 41.80%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 0.40%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 71.30% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

[bold-text]Are Institutional Investors Increasing Stakes in IMGN Shares?[/bold-text]

It appears that more than several institutional investors and hedge funds decided to increase stakes in IMGN in the recent period. That is how Wellington Management Co. LLP now has an increase position in IMGN by 21.72% in the first quarter, owning 23.31 million shares of IMGN stocks, with the value of $83.92 million after the purchase of an additional 4,160,256 shares during the last quarter. In the meanwhile, BlackRock Fund Advisors also increased their stake in IMGN shares changed 4.53% in the first quarter, which means that the company now owns 12.91 million shares of company, all valued at $46.48 million after the acquisition of additional 559,934 shares during the last quarter.

SSgA Funds Management, Inc. acquired a new position in ImmunoGen, Inc. during the first quarter, with the value of $33.06 million, and Assenagon Asset Management SA increased their stake in the company’s shares by 2,728.55% in the first quarter, now owning 4,811,013 shares valued at $17.95 million after the acquisition of the additional 4.99 million shares during the last quarter. In the end, Millennium Management LLC increased their position by 2.21% during the first quarter, now owning 3.99 million IMGN shares, now holding the value of $14.35 million in IMGN with the purchase of the additional 2,007,736 shares during the period of the last quarter. At the present, 71.30% of IMGN shares are in the ownership of institutional investors.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

3 Top Biotech Stocks to Watch

Companies in the biotechnology industry work on the development of drugs and diagnostic technologies to treat medical conditions and diseases. Most Biotech products must undergo